Loading...
Market
Story
Ro Partners with Eli Lilly to Offer Lower-Priced Zepbound Vials with Cash-Pay Option
Dec 11, 2024, 01:42 PM
Telehealth company Ro has partnered with pharmaceutical giant Eli Lilly to expand access to Zepbound, a weight-loss drug containing tirzepatide. The partnership will enable Ro to offer lower-priced, single-dose vials of Zepbound through LillyDirect, Eli Lilly's self-pay pharmacy channel. Ro patients with on-label prescriptions will have access to the drug starting Wednesday, with a cash-pay option available. This collaboration comes amid ongoing shortages of semaglutide-based drugs, such as Ozempic, and questions about the future of compounded GLP-1 treatments. The announcement has impacted the stock performance of Hims & Hers Health, Inc. (HIMS), a company that sells compounded semaglutide, with shares falling 3.8% pre-market.
View original story
Similar markets
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than 500,000 units • 25%
500,000 to 1 million units • 25%
1 million to 2 million units • 25%
More than 2 million units • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%